The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Illumina Reports Financial Results for Second Quarter 2011

Tuesday, July 26, 2011

Illumina Reports Financial Results for Second Quarter 201116:01 EDT Tuesday, July 26, 2011 SAN DIEGO (Business Wire) -- Illumina, Inc. (NASDAQ:ILMN) today announced its financial results for the second quarter of 2011. Second quarter 2011 results include: Revenue of $287.5 million, a 36% increase over the $212.0 million reported in the second quarter of 2010. GAAP net income of $30.6 million, or $0.22 per diluted share, compared to net income of $29.8 million, or $0.21 per diluted share, for the second quarter of 2010. This represents a 4% increase to GAAP earnings per diluted share. Non-GAAP net income of $52.5 million, or $0.38 per diluted share, compared to $34.0 million, or $0.26 per diluted share, for the second quarter of 2010 (see the table entitled “Itemized Reconciliation Between GAAP and Non-GAAP Net Income”). This represents a 46% increase to non-GAAP earnings per diluted share. Gross margin in the second quarter of 2011 was 67.3% compared to 68.9% in the prior year period. Excluding the effect of non-cash charges associated with stock compensation and the amortization of acquired intangibles, non-GAAP gross margin was 69.0% for the second quarter of 2011 compared to 70.3% in the prior year period. Research and development (R&D) expenses for the second quarter of 2011 were $50.8 million compared to $43.7 million in the second quarter of 2010. R&D expenses included $8.5 million and $6.0 million of non-cash stock compensation expense in the second quarters of 2011 and 2010, respectively. Excluding these charges and contingent compensation expense, R&D expenses as a percentage of revenue were 14.1% compared to 17.3% in the prior year period. Selling, general and administrative (SG&A) expenses for the second quarter of 2011 were $69.2 million compared to $53.1 million for the second quarter of 2010. SG&A expenses included $13.3 million and $9.4 million of non-cash stock compensation expense in the second quarters of 2011 and 2010, respectively. SG&A expenses also included contingent compensation expense and amortization of acquired intangibles in the second quarter of 2011. Excluding these charges, SG&A expenses as a percentage of revenue were 19.1% compared to 20.6% in the prior year period. The company generated $71.2 million in cash flow from operations during the second quarter of 2011 compared to $77.2 million in the prior year period. Depreciation and amortization expenses were $16.5 million and capital expenditures were $16.2 million during the second quarter. The company ended the second quarter with $1.2 billion in cash and short-term investments compared to $894.3 million as of January 2, 2011. Highlights since our last earnings release Commenced early access shipments of MiSeq, a low-cost personal sequencing system that provides individual researchers a platform with rapid turnaround time, unmatched accuracy, and radically improved ease of use. Commenced commercial shipments of our TruSeq SBS Kit V3, delivering a three-fold improvement to approximately 600G of output per run and improving accuracy. Commenced shipment of the HumanOmni5-Quad BeadChip, a four-sample microarray that can genotype up to 5 million markers per sample. Announced the University of Washington Department of Genome Sciences joined the IGN and reduced the price for sequencing whole human genomes through the Illumina Genome Network (IGN) to $5,000 per genome for projects of ten samples or more, and $4,000 for projects of 50 samples or more. Adjusted the price of our Individual Genome Sequencing (IGS) service to $9,500 for consumers, $7,500 for patients with a life-threatening illness, and $10,000 for cancer patients requiring a tumor-normal pair. Announced the availability of new TruSeq Custom Enrichment kits, which enable researchers to economically design and target genomic regions of interest. Announced the company has been selected as a preferred service provider for Cancer Research UK, the world's leading cancer charity, to sequence up to 1,500 whole human genome samples. Financial outlook and guidance The non-GAAP financial guidance discussed below excludes the following items (see the table entitled “Reconciliation of Non-GAAP Financial Guidance” for a reconciliation of these GAAP and non-GAAP financial measures): Charges associated with relocating the company's corporate headquarters. Loss on the extinguishment of debt. Non-cash interest expense and the double dilution associated with the accounting treatment of the company's outstanding convertible debt and the corresponding call option overlay. Amortization of acquired intangible assets. Contingent compensation expense. Acquisition related expenses. As a result of the Company's financial performance in the first half of the year we are updating our financial guidance. We now expect: Revenue growth for fiscal 2011 of 24 - 26% from fiscal 2010 revenue of $902.7 million. For the year, gross margin is expected to range from 69.0 - 70.0%. Non-GAAP earnings per diluted share to grow 33 - 36% from 2010 non-GAAP earnings per diluted share of $1.06. Quarterly conference call information The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Tuesday, July 26, 2011. Interested parties may listen to the call by dialing 866-770-7146 (passcode: 43976139), or if outside North America, by dialing +1-617-213-8068 (passcode: 43976139). Individuals may access the live teleconference in the Investor Relations section of Illumina's web site under the “Company” tab at www.illumina.com. A replay of the conference call will be available from 4:30pm Pacific Time (7:30pm Eastern Time) on July 26, 2011 through August 2, 2011 by dialing 888-286-8010 (passcode: 20537846), or if outside North America, by dialing +1-617-801-6888 (passcode: 20537846). Statement regarding use of non-GAAP financial measures The company reports non-GAAP results for diluted net income per share, net income, gross margins, operating margins, other income, and free cash flow in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The company's financial measures under GAAP include substantial non-cash and other charges related to stock compensation expense, loss on the extinguishment of convertible debt, non-cash interest expense associated with the company's convertible debt instruments that may be settled in cash, in-process research and development and contingent compensation expense, amortization expense related to acquired intangible assets, headquarter relocation expense, changes in the fair value of contingent consideration, a gain on the acquisition of an investee accounted for using the cost method of accounting prior to acquisition, and acquisition related transaction expenses. Per share amounts also include the double dilution associated with the accounting treatment of the company's 0.625% convertible senior notes outstanding and the corresponding call option overlay. Management believes that presentation of operating results that excludes these charges and per share double dilution provides useful supplemental information to investors and facilitates the analysis of the company's core operating results and comparison of operating results across reporting periods. Management also believes that this supplemental non-GAAP information is therefore useful to investors in analyzing and assessing the company's past and future operating performance. The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release. Use of forward looking statements Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to develop and commercialize further our sequencing, BeadArray™, VeraCode®, Eco™, and consumables technologies and to deploy new sequencing, genotyping, gene expression, and diagnostics products and applications for our technology platforms, (ii) our ability to manufacture robust instrumentation and consumables, and (iii) reductions in the funding levels to our primary customers, including as the result of timing and amount of funding provided by the American Recovery and Reinvestment Act of 2009, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current financial quarter. About Illumina Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare. Illumina, Inc.Condensed Consolidated Balance Sheets(In thousands)     July 3, 2011January 2, 2011ASSETS(unaudited) Current assets: Cash and cash equivalents $ 261,084 $ 248,947 Short-term investments 972,830 645,342 Accounts receivable, net 193,431 165,598 Inventory, net 142,583 142,211 Deferred tax assets, current portion 22,450 19,378 Prepaid expenses and other current assets   30,937   36,922 Total current assets 1,623,315 1,258,398 Property and equipment, net 129,762 129,874 Goodwill 321,853 278,206 Intangible assets, net 112,708 91,462 Deferred tax assets, long-term portion 16,990 39,497 Other assets   52,358   41,676 Total assets $ 2,256,986 $ 1,839,113   LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 58,270 $ 66,744 Accrued liabilities 185,536 156,164 Long-term debt, current portion   40,649   311,609 Total current liabilities 284,455 534,517 Long-term debt 757,274 - Other long-term liabilities 38,512 28,531 Conversion option subject to cash settlement 8,441 78,390 Stockholders' equity   1,168,304   1,197,675 Total liabilities and stockholders' equity $ 2,256,986 $ 1,839,113   Illumina, Inc.Condensed Consolidated Statements of Income(In thousands, except per share amounts)(unaudited)         Three Months EndedSix Months EndedJuly 3,July 4,July 3,July 4,2011201020112010 Revenue: Product revenue $ 269,871 $ 198,538 $ 536,588 $ 372,217 Service and other revenue   17,579     13,465     33,377     31,917   Total revenue   287,450     212,003     569,965     404,134   Cost of Revenue: Cost of product revenue (a) 84,518 59,627 169,955 112,566 Cost of service and other revenue (a) 6,541 4,690 12,593 10,084 Amortization of acquired intangible assets   3,035     1,595     6,020     3,215   Total cost of revenue   94,094     65,912     188,568     125,865   Gross profit   193,356     146,091     381,397     278,269   Operating Expenses: Research and development (a) 50,801 43,667 101,001 87,343 Selling, general and administrative (a) 69,233 53,135 134,894 103,414 Acquisition related expense, net 4,770 1,861 5,040 1,861 Headquarter relocation expense   2,542     -     5,064     -   Total operating expenses   127,346     98,663     245,999     192,618   Income from operations 66,010 47,428 135,398 85,651 Other expense, net   (16,986 )   (902 )   (50,366 )   (5,765 ) Income before income taxes 49,024 46,526 85,032 79,886 Provision for income taxes   18,404     16,730     30,275     28,882   Net income $ 30,620   $ 29,796   $ 54,757   $ 51,004   Net income per basic share $ 0.25   $ 0.24   $ 0.44   $ 0.42   Net income per diluted share $ 0.22   $ 0.21   $ 0.37   $ 0.37   Shares used in calculating basic net income per share   123,456     123,095     124,987     121,882   Shares used in calculating diluted net income per share   141,765     140,951     147,447     138,682                     (a) Includes total stock-based compensation expense for stock based awards:   Three Months EndedSix Months EndedJuly 3,July 4,July 3,July 4,2011201020112010 Cost of product revenue $ 1,800 $ 1,301 $ 3,312 $ 2,510 Cost of service and other revenue 132 $ 146 342 $ 257 Research and development 8,461 $ 6,032 16,188 $ 11,930 Selling, general and administrative   13,273   $ 9,366     25,863   $ 19,147   Stock-based compensation expense before taxes $ 23,666   $ 16,845   $ 45,705   $ 33,844                       Illumina, Inc.Condensed Consolidated Statements of Cash Flows(In thousands)(unaudited)         Three Months EndedSix Months EndedJuly 3,July 4,July 3,July 4,   2011     2010     2011     2010   Net cash provided by operating activities $ 71,220 $ 77,199 $ 159,798 $ 136,264 Net cash used in investing activities (272,264 ) (96,460 ) (425,140 ) (121,124 ) Net cash provided by financing activities 51,517 43,216 276,998 77,522 Effect of exchange rate changes on cash and cash equivalents   270     7     481     (108 ) Net (decrease) increase in cash and cash equivalents (149,257 ) 23,962 12,137 92,554 Cash and cash equivalents, beginning of period   410,341     213,225     248,947     144,633   Cash and cash equivalents, end of period $ 261,084   $ 237,187   $ 261,084   $ 237,187     Calculation of free cash flow (a): Net cash provided by operating activities $ 71,220 $ 77,199 $ 159,798 $ 136,264 Purchases of property and equipment   (16,203 )   (13,142 )   (28,503 )   (24,322 ) Free cash flow $ 55,017   $ 64,057   $ 131,295   $ 111,942     (a) Free cash flow, which is a non-GAAP financial measure, is calculated as net cash provided by operating activities reduced by purchases of property and equipment. Free cash flow is useful to management as it is one of the metrics used to evaluate our performance and to compare us with other companies in our industry. However, our calculation of free cash flow may not be comparable to similar measures used by other companies.   Illumina, Inc.Results of Operations - Non-GAAP(In thousands, except per share amounts)(unaudited)         ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP NET INCOME PER SHARE:   Three Months EndedSix Months EndedJuly 3,July 4,July 3,July 4,   2011     2010     2011     2010   GAAP net income per share - diluted$0.22$0.21$0.37$0.37 Pro forma impact of weighted average shares (a) 0.01 0.02 0.03 0.01 Adjustments to net income: Loss on extinguishment of debt 0.07 - 0.26 - Non-cash interest expense (b) 0.06 0.04 0.10 0.08 Acquisition related expense (gain), net (c) 0.03 (0.01 ) 0.04 (0.01 ) Amortization of acquired intangible assets 0.02 0.01 0.04 0.03 Contingent compensation expense (d) 0.02 0.01 0.03 0.02 Headquarter relocation expense (e) 0.02 - 0.04 - Incremental non-GAAP tax expense (f)   (0.07 )   (0.02 )   (0.18 )   (0.04 ) Non-GAAP net income per share - diluted (g) $ 0.38   $ 0.26   $ 0.73   $ 0.46   Shares used in calculating non-GAAP diluted net income per share   139,357     132,547     140,767     130,757     ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP NET INCOME:   GAAP net income$30,620$29,796$54,757$51,004 Loss on extinguishment of debt 9,679 - 36,856 - Non-cash interest expense (b) 8,252 5,156 14,753 10,210 Acquisition related expense (gain), net (c) 4,770 (1,053 ) 5,040 (1,053 ) Amortization of acquired intangible assets 3,328 1,595 6,313 3,215 Contingent compensation expense (d) 2,706 919 4,830 1,838 Headquarter relocation expense (e) 2,542 - 5,064 - Incremental non-GAAP tax expense (f)   (9,407 )   (2,377 )   (24,856 )   (4,620 ) Non-GAAP net income (g) $ 52,490   $ 34,036   $ 102,757   $ 60,594     ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP DILUTED NUMBER OF SHARES:   Weighted average shares used in calculation of GAAP diluted net income per share 141,765 140,951 147,447 138,682 Weighted average dilutive potential common shares issuable of redeemable convertible senior notes (a)   (2,408 )   (8,404 )   (6,680 )   (7,925 ) Weighted average shares used in calculation of Non-GAAP diluted net income per share   139,357     132,547     140,767     130,757                     (a) Pro forma impact of weighted average shares represents the impact of double dilution associated with the accounting treatment of the company's outstanding convertible debt and the corresponding call option overlay.   (b) Non-cash interest expense is calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash.   (c) Acquisition related expense (gain), net includes an acquired in-process research and development charge of $5.4 million in Q2 2011 related to a milestone payment for a prior acquisition, offset by a loss of $0.3 million in Q1 2011 and a gain of $0.7 million in Q2 2011 recorded for changes in fair value of contingent consideration. Prior year adjustments include a gain on acquisition of $2.9 million recorded in Q2 2010 for the difference between the carrying value of a cost method investment prior to acquisition and the fair value of that investment at the time of acquisition, an acquired in-process research and development charge of $1.3 million in Q2 2010 and acquisition expense of $0.5 million in Q2 2010.   (d) Contingent compensation expense represents contingent consideration for post-combination services associated with acquisitions.   (e) Headquarter relocation expense in Q2 2011 and the first half of 2011 represents accelerated depreciation expense recorded in anticipation of the exit of our current headquarter facilities. During 2011, we expect to incur additional headquarter relocation expenses, the majority of which are non-cash in nature. These expenses include items such as a cease-use loss upon vacating our current headquarters, accelerated depreciation of certain property and equipment, and double rent expense during the transition to the new facility.   (f) Incremental non-GAAP tax expense reflects the increase to GAAP tax expense related to the non-GAAP adjustments listed above.   (g) Non-GAAP net income per share and net income exclude the effect of the pro forma adjustments as detailed above. Non-GAAP diluted net income per share and net income are key drivers of our core operating performance and major factors in management's bonus compensation each year. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing our past and future core operating performance.   Illumina, Inc.Results of Operations - Non-GAAP (continued)(Dollars in thousands)(unaudited)   ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP RESULTS OF OPERATIONS AS A PERCENT OF REVENUE:     Three Months Ended   Six Months EndedJuly 3, 2011   July 4, 2010July 3, 2011   July 4, 2010GAAP gross profit$193,356   67.3%$146,091   68.9%$381,397   66.9%$278,269   68.9% Stock-based compensation expense 1,932 0.7 % 1,447 0.7 % 3,654 0.6 % 2,767 0.7 % Amortization of acquired intangible assets   3,035   1.1 %   1,595   0.8 %   6,020   1.1 %   3,215   0.8 % Non-GAAP gross profit $ 198,323   69.0 % $ 149,133   70.3 % $ 391,071   68.6 % $ 284,251   70.3 %   Research and development expense$50,80117.7%$43,66720.6%$101,00117.7%$87,34321.6% Stock-based compensation expense (8,461 ) (2.9 %) (6,032 ) (2.8 %) (16,188 ) (2.8 %) (11,930 ) (3.0 %) Contingent compensation expense (a)   (1,855 ) (0.6 %)   (919 ) (0.4 %)   (3,292 ) (0.6 %)   (1,838 ) (0.5 %) Non-GAAP research and development expense $ 40,485   14.1 % $ 36,716   17.3 % $ 81,521   14.3 % $ 73,575   18.2 %   Selling, general and administrative expense$69,23324.1%$53,13525.1%$134,89423.7%$103,41425.6% Stock-based compensation expense (13,273 ) (4.6 %) (9,366 ) (4.4 %) (25,863 ) (4.5 %) (19,147 ) (4.7 %) Contingent compensation expense (a) (851 ) (0.3 %) - - (1,538 ) (0.3 %) - - Amortization of acquired intangible assets   (293 ) (0.1 %)   -   -     (293 ) (0.1 %)   -   -   Non-GAAP selling, general and administrative expense $ 54,816   19.1 % $ 43,769   20.6 % $ 107,200   18.8 % $ 84,267   20.9 %   GAAP operating profit$66,01023.0%$47,42822.4%$135,39823.8%$85,65121.2% Stock-based compensation expense 23,666 8.2 % 16,845 7.9 % 45,705 8.0 % 33,844 8.4 % Acquisition related expense, net (b) 4,770 1.7 % 1,861 0.9 % 5,040 0.9 % 1,861 0.5 % Amortization of acquired intangible assets 3,328 1.1 % 1,595 0.8 % 6,313 1.1 % 3,215 0.8 % Contingent compensation expense (a) 2,706 0.7 % 919 0.4 % 4,830 0.8 % 1,838 0.5 % Headquarter relocation expense (c)   2,542   0.9 %   -   -     5,064   0.9 %   -   -   Non-GAAP operating profit (d) $ 103,022   35.8 % $ 68,648   32.4 % $ 202,350   35.5 % $ 126,409   31.3 %   GAAP other expense, net$(16,986)(5.9%)$(902)(0.4%)$(50,366)(8.8%)$(5,765)(1.4%) Loss on extinguishment of debt 9,679 3.4 % - - 36,856 6.5 % - - Acquisition related gain (b) - - (2,914 ) (1.4 %) - - (2,914 ) (0.7 %) Non-cash interest expense (e)   8,252   2.9 %   5,156   2.4 %   14,753   2.6 %   10,210   2.5 % Non-GAAP other income, net (d) $ 945   0.3 % $ 1,340   0.6 % $ 1,243   0.2 % $ 1,531   0.4 %   (a) Contingent compensation expense represents contingent consideration for post-combination services associated with acquisitions.   (b) Acquisition related expense, net includes an acquired in-process research and development charge of $5.4 million in Q2 2011 related to a milestone payment for a prior acquisition, offset by a loss of $0.3 million in Q1 2011 and a gain of $0.7 million in Q2 2011 recorded for changes in fair value of contingent consideration. Acquisition related expense, net in prior year periods include an acquired in-process research and development charge of $1.3 million in Q2 2010 and acquisition expense of $0.5 million in Q2 2010. Acquisition related gain in prior year represents a gain on acquisition of $2.9 million recorded in Q2 2010 for the difference between the carrying value of a cost method investment prior to acquisition and the fair value of that investment at the time of acquisition.   (c) Headquarter relocation expense in Q2 2011 and the first half of 2011 represents accelerated depreciation expense recorded in anticipation of the exit of our current headquarter facilities. During 2011, we expect to incur additional headquarter relocation expenses, the majority of which are non-cash in nature. These expenses include items such as a cease-use loss upon vacating our current headquarters, accelerated depreciation of certain property and equipment, and double rent expense during the transition to the new facility.   (d) Non-GAAP operating profit, and non-GAAP other income, net, exclude the effects of the pro forma adjustments as detailed above. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing our past and future core operating performance. Non-GAAP gross profit, included within the non-GAAP operating profit, is a key measure of the effectiveness and efficiency of our manufacturing processes, product mix and the average selling prices of our products and services.   (e) Non-cash interest expense is calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash.   Illumina, Inc.Reconciliation of Non-GAAP Financial Guidance   The financial guidance provided below is an estimate based on information available as of July 26, 2011. The company's future performance and financial results are subject to risks and uncertainties, and actual results could differ materially from the guidance set forth below. Some of the factors that could affect the company's financial results are stated above in this press release. More information on potential factors that could affect the company's financial results is included from time to time in the company's public reports filed with the SEC, including the company's Form 10-K for the fiscal year ended January 2, 2011, the company's Form 10-Q for the fiscal quarter ended April 3, 2011, and the company's Form 10-Q for the fiscal quarter ended July 3, 2011 to be filed with the SEC. The company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates. Diluted net income per share   Fiscal Year 2011   Non-GAAP $1.41 - $1.44   Headquarter relocation expense (a) (0.24)   Loss on extinguishment of debt (0.17)   Non-cash interest expense (b) (0.14)   Amortization of intangible assets (0.06)   Contingent compensation expense (c) (0.04)   Acquisition related expense, net (d) (0.02)   Pro forma impact of weighted average shares (e) (0.01)   GAAP$0.73 - $0.76         (a) Under the terms of a lease agreement executed by the company in Q4 2010, the company's headquarters will move to a new location during the second half of 2011. We expect to incur headquarter relocation expenses, the majority of which are non-cash in nature. These expenses include items such as a cease-use loss upon vacating our current headquarters, accelerated depreciation of certain property and equipment, and double rent expense during the transition to the new facility.   (b) Non-cash interest expense is calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash.   (c) Contingent compensation expense represents contingent consideration for post-combination services associated with acquisitions.   (d) Acquisition related expense, net includes an acquired in-process research and development charge related to a milestone payment for a prior acquisition and net changes in fair value of contingent consideration.   (e) Pro forma impact of weighted average shares represents the estimated impact of double dilution associated with the accounting treatment of the company's outstanding convertible debt and the corresponding call option overlay. Illumina, Inc.Investors:Kevin Williams, MDInvestor Relations858-332-4989kwilliams@illumina.comorMedia:Laura TrotterPublic Relations858-882-6822PR@illumina.com